The DNA / Catalyst Licensing Model
Cisco DNA licensing is a per-device subscription model: every switch, access point, and routing device managed through the platform requires its own licence, at the tier that unlocks the features you intend to use. The platform itself — long known as DNA Center — is now Catalyst Centre following Cisco's 2026 rebranding, and the newer Catalyst software subscription for switching sits alongside the established DNA software subscriptions for switching and wireless.
Because the model is per device, the tier you choose is not a single decision but one multiplied across the entire estate. A tier difference of a few hundred dollars per switch becomes a seven-figure difference across a few thousand devices over a multi-year term. That makes DNA licensing one of the highest-leverage line items in any Cisco Enterprise Agreement — and a frequent source of recoverable spend, as set out in the Cisco Enterprise Agreement and licensing guide.
Essentials vs Advantage vs Premier
The tiers are cumulative: each adds capability on top of the one below, at a higher per-device price. The question for every device is not "which tier is best" but "which tier matches the features this device will actually run".
| Tier | Key Capabilities | Indicative 3-Yr Cost (9300-class) |
|---|---|---|
| Essentials | Visibility, provisioning, device health, software image management, basic assurance | $700–$900 |
| Advantage | Adds AI Network Analytics, LAN automation, segmentation, SD-Access, packet analysis, ISE Advantage | $1,200–$1,500 |
| Premier | Adds advanced security analytics, deeper security-portfolio integration, predictive AI, compliance reporting | Above Advantage |
Essentials covers the fundamentals most networks rely on day to day. Advantage is the tier Cisco's account teams push hardest, because it carries the differentiated, higher-margin features — SD-Access and segmentation chief among them. Premier sits above Advantage for regulated and security-intensive environments. The pricing gap between Essentials and Advantage — roughly $500 per device over three years on enterprise switches — is exactly the gap that over-tiering converts into shelfware. For the commercial framing of how these tiers land inside an EA, see the Cisco EA negotiation and pricing guide.
The ISE Bundle Inside Advantage
One genuine reason to choose Advantage is the bundled Identity Services Engine entitlement: Catalyst/DNA Advantage includes ISE Advantage licences, with the quantity dependent on the switch model — though ISE licences are not available on the Catalyst 9200 series. Where you genuinely run ISE for network access control, this bundling is real value that should be counted when comparing the tiers.
The caveat is that the ISE bundle should not, on its own, justify Advantage across the whole estate. If only part of the network runs ISE, licensing every switch at Advantage to capture ISE entitlement you use on a fraction of devices is a false economy. Map where ISE is actually deployed and tier accordingly. The compliance side of tracking these entitlements is covered in the Cisco Smart Licensing compliance guide.
The Over-Tiering Trap
The single most common — and most expensive — DNA licensing mistake is over-tiering: holding Advantage on every switch and access point when most of the estate uses only Essentials-level features. Because Catalyst Centre licenses per device at the tier that unlocks the features you intend to use, paying for Advantage on devices that never run SD-Access, segmentation, or AI analytics is pure shelfware.
Run a feature-utilisation review before any renewal: which devices actually use SD-Access, segmentation, or AI Network Analytics, and which only run Essentials-level functions? On a 3,000-switch estate, moving the devices that never touch Advantage features down a tier saves roughly $500 per device over three years — $1.5M that was buying nothing.
The discipline is the same one that governs the whole Cisco estate: tier to documented feature usage, not to the vendor's "standardise on Advantage for simplicity" recommendation. Standardisation has an operational appeal, but it is not free, and the cost falls on the licence line for the full term. This is the device-level version of the right-sizing principle applied across suites in the Cisco subscription licensing transition guide.
Switching and Wireless Nuances
DNA software is sold separately for switching and wireless, and the two estates often have different feature needs. The Catalyst software subscription for switching is newer and switching-specific, while DNA software subscriptions cover wireless; both follow the Essentials/Advantage split, and base product-level support with a four-hour TAC response objective for severity 1 and 2 cases is included at both tiers. Treat the wireless and switching estates as separate sizing exercises rather than applying one tier decision across both.
Access points and switches each consume their own licence, so a campus refresh that adds wireless coverage adds licence demand independently of the switching estate. Modelling these as distinct lines — and checking which Catalyst Centre features each estate genuinely uses — prevents the wireless rollout from silently dragging the whole network up to Advantage. The cloud-managed alternative for parts of the estate is covered in the Cisco Meraki licensing guide.
Optimising and Negotiating DNA Licensing
Optimising DNA licensing is a two-step exercise: first right-tier, then negotiate. Right-tiering means a feature-utilisation audit that maps every device to the lowest tier covering the features it actually runs, downgrading the over-tiered majority and reserving Advantage and Premier for the devices that genuinely use their differentiated capabilities. That audit alone routinely surfaces six- and seven-figure savings on a large estate.
Negotiating means folding the right-tiered DNA estate into the wider Cisco EA discount conversation, where the committed value across suites drives the discount band, and protecting flexibility with reallocation rights so devices can move tiers as needs change. Done together, right-tiering and negotiation turn DNA licensing from a quietly compounding cost into a controlled, evidenced line. To run a DNA tier-utilisation review before your next Cisco renewal, request a confidential briefing, or download our Cisco EA Playbook.